Predatory bacteria can protect SKH-1 mice from a lethal plague challenge

James S. Findlay, Helen C. Flick-Smith, Emma Keyser, Ian A. Cooper, E. Diane Williamson & Petra C. F. Oyston

With the rise of antimicrobial resistance, novel ways to treat bacterial infections are required and the use of predatory bacteria may be one such approach. *Bdellovibrio* species have been shown in vitro to predate on a wide range of other Gram-negative bacteria, including CDC category A/B pathogens such as *Yersinia pestis*. The data reported here show that treatment of SKH-1 mice with *Bdellovibrio bacteriovorus* HD100 provided significant protection from a lethal challenge of *Yersinia pestis* CO92. This is the first report of protection conferred by predation in vivo against a systemic pathogen challenge. However, this protective effect was not observed in a preliminary study with Balb/c mice. Therefore the effects of the predatory bacteria are complex and may be dependent on immune status/genetics of the host. Overall, predatory bacteria may have utility as a therapeutic modality but further work is required to understand the predator-host interaction.

Over recent decades, there has been a reduction in the rate of discovery of new antibiotics whilst there has also been an increase in resistance to existing antibiotics, a situation that has spawned the term "antibiotic apocolypse". Therefore there is a need to develop new therapies to treat bacterial infections. *Bdellovibrio* and like organisms (BALOs) are small, Gram-negative bacteria, found in both terrestrial and aquatic environments, that predate on other Gram-negative bacteria. *Bdellovibrio* enter the periplasmic space of the prey bacteria, replicate and then lyse the prey to release progeny predator. Therefore one such approach to treating bacterial infections could be to use predatory bacteria such as *Bdellovibrio* as a ‘living’ antibiotic.

Recently, there has been increasing research evaluating predatory bacteria in vitro for their ability to kill a range of Gram-negative bacteria from diverse genera, including multi-drug resistant clinical isolates. In turn this has led to research into the efficacy of *Bdellovibrio* species to treat bacterial infections in vivo, as well as evaluation of the safety profile of administration of predatory bacteria. As a Gram-negative organism, there would be concern about endotoxin having a detrimental effect on the host. Early studies showed that in addition to the degradation of macromolecular compounds of the prey to provide nutrition for the invading bacteria, *Bdellovibrio* recycled outer membrane proteins, lipid A, and fatty acids of the prey for integration into its own membrane system. It has been demonstrated that the *Bdellovibrio* LPS is chemically different from the prey upon which the bacteria had fed: the lipid A has an unusual chemical structure which conferred low endotoxic activity in cytokine induction assays. Initial work demonstrated that oral administration of predatory bacteria to young chicks was not associated with any adverse effects. A subsequent study showed that inoculation of C57BL/6 mice with *Bdellovibrio* via the intranasal (i.n.) and intravenous (i.v.) routes resulted in an initial host response to the predator, and these pro-inflammatory cytokines (IL-1β, IL-6, IL-10, CXCL-1/KC, IFN-γ and TNF-α) returned to baseline levels after 18 hours. Similar results were obtained in rats. Efficacy of predatory bacteria to control bacterial infections in vivo has been tested in a range of models. Injection into the hindbrain of zebrafish with *Bdellovibrio* increased survival of *Shigella*-infected zebrafish and the protective effect was the outcome of synergy between bacterial predation and host immunity. Efficacy has been reported in control of bacteria on surfaces: studies on *K. pneumoniae* in rats demonstrated that *Bdellovibrio* can reduce pathogen burden in lungs. However, the predator was not able to control intravenously administered *Klebsiella* circulating in blood nor dissemination to the other organs, leading the researchers to suggest that "predatory bacteria may not be effective for treatment of acute blood infections". Similarly, in an experimentally induced infectious bovine keratoconjunctivitis model, treatment with *Bdellovibrio* was similarly ineffective.
although the experimental model used produced lesions that did not mimic naturally occurring disease well\textsuperscript{16}. Therefore, although in vivo studies demonstrated that the predatory bacteria had no obvious deleterious effects, efficacy in vivo has not been demonstrated convincingly. However, due to the pressing need for new approaches to combat infectious disease, interest remains high. We hypothesised that as the zebrafish model demonstrated a synergy between predation and host immunity, it may be that protective effects may be missed due to the model employed\textsuperscript{14}. We wished to evaluate this hypothesis in a well-characterised systemic, acute disease model.

Predatory bacteria may have utility as a therapy to treat biological threat agents, including the pathogen \textit{Yersinia pestis}, the causative agent of plague\textsuperscript{17}. \textit{Y. pestis} is a Gram-negative bacterium mainly infecting small mammals and is most commonly transmitted to humans by flea vectors to cause bubonic plague. Plague is endemic in a number of countries and is associated with seasonal outbreaks, such as the 2017 outbreak in Madagascar. Plague can be transmitted in infectious aerosols to cause pneumonic disease, with a case-fatality rate of up to 100\% and antimicrobial resistant isolates have been identified\textsuperscript{18,19}. Although the pathogen has an obligate intracellular phase during infection, \textit{Y. pestis} is primarily an extracellular pathogen (as reviewed in\textsuperscript{20}). As such, antibodies can be sufficient for protection following vaccination\textsuperscript{21}. As \textit{Bdellovibrio} can predate \textit{Y. pestis} in vitro\textsuperscript{17}, we considered that systemic plague may be a suitable challenge on which to test our hypothesis, especially as the mouse model has been extensively characterised. Therefore in this study, the ability of \textit{Bacteriovorus} HD100 to predate \textit{Y. pestis} in vivo and potentially protect mice from a lethal challenge was investigated.

**Results**

\textbf{\textit{Bdellovibrio} can survive phagocytosis by murine macrophages in vitro.} As \textit{Y. pestis} has an intracellular phase during infection, we initially wished to determine whether \textit{Bacteriovorus} HD100 was able to survive in murine macrophages following phagocytosis. This would be important for identifying if the predator could target the intracellular \textit{Y. pestis} prey, which persist in phagosomes, or would be limited to targeting extracellular prey. Using a mCherry-expressing strain of \textit{Bacteriovorus} HD100 (HD100:mCherry), an uptake assay was carried out on J774A.1 cells. No cell detachment or cytopathic effect was observed in infected versus uninfected macrophages. Whilst predator numbers reduced over time (approximately a three-log drop in viable predator by 24 hours), predator could still be isolated from J774A.1 cells suggesting that \textit{Bacteriovorus} HD100:mCherry could enter macrophages and survive following phagocytosis (Fig. 1a). To confirm that the predator was intracellular, J774.1 cells with \textit{Bacteriovorus} HD100:mCherry were infected and stained 3 hours post infection using Lysotracker Deep-Red (which only emits a strong signal under acidic conditions such as within organelles) and analysed via ImageStream. A mCherry signal could be detected and upon analysis, nearly all the signal (94 ± 0.49\%) was co-localised with the Lysotracker signal, indicating that the vast majority of \textit{Bacteriovorus} HD100 in these cells 3 hours post infection were intracellular and appeared to be within the phagosome (Fig. 1b). Therefore \textit{Bacteriovorus} HD100:mCherry appeared to be able to survive intracellularly for sufficient time relevant to the treatment of an intracellular infection.

\textbf{Monitoring \textit{Bdellovibrio} in vivo.} To determine persistence and tropism of \textit{Bacteriovorus} HD100 in vivo, mice were inoculated with a single dose of \textit{Bacteriovorus} HD100:mCherry and the spread of the mCherry signal was followed with in vivo imaging. To reduce issues caused by auto-fluorescence of fur, SKH-1 mice (which are naturally hairless) were used. The predator was inoculated via four different routes at the following doses:
HD100 was controlling the spread of *B. bacteriovorus* (Fig. 5b). Subsequent enumeration of viable bacteria in the spleen at the end of the study identified three of the four mice which survived had no detectable bacteria and <10 cfu were detected in the other mouse, indicating that *B. bacteriovorus* HD100 provides protection by controlling spread of *Y. pestis* and achieving clearance of organs.

Previous data in zebrafish showed that the host's response could enhance the activity of the predatory bacteria. To determine if the predatory bacteria *B. bacteriovorus* HD100 were able to protect mice from a lethal challenge of *Y. pestis*, SKH-1 were pre-treated with *B. bacteriovorus* HD100:mCherry via the i.p. route and then infected with 1116 cfu (average across three experiments) of *Y. pestis* CO92 pGEN-luxCDABE via the s.c. route. Starting 24 hours after infection, mice were treated with predator daily and the spread of *Y. pestis* was followed using imaging. Treatment of mice with *B. bacteriovorus* HD100:mCherry resulted in a significant protection (p < 0.05) in two of the three studies (Fig. 5a). When analysed using a stratified log rank test, the predatory bacteria provided a highly significant (p < 0.001) protective effect from a lethal challenge of *Y. pestis* CO92 pGEN-luxCDABE. Mice which survived had no clinical signs and had a significantly lower level of luciferase signal on the ventral side, suggesting that *B. bacteriovorus* HD100 was controlling the spread of *Y. pestis* from the site of infection (Fig. 5b). Subsequent enumeration of viable bacteria in the spleen at the end of the study identified three of the four mice which survived had no detectable bacteria and <10 cfu were detected in the other mouse, indicating that *B. bacteriovorus* HD100 provides protection by controlling spread of *Y. pestis* and achieving clearance of organs.

**Discussion**

This study has demonstrated that *B. bacteriovorus* HD100 provided significant protection from a systemic challenge of *Y. pestis* in SKH-1 mice. This is the first report of protection against systemic challenge in a mammalian model. However, it must be reported that in a small, preliminary study in Balb/c mice, *B. bacteriovorus* HD100 did not show protection. Further studies will be required to validate this preliminary observation.

In this study, there appeared to be an adipose tissue tropism of *Bdellovibrio in vivo*. This has not previously been observed, but probably because previous studies in mice used culture of prey bacteria or qPCR of organ extracts as the output, rather than whole body imaging, as used here. The interaction of predatory and prey bacteria in the zebrafish model would also not have indicated this phenomenon due to different anatomy between piscan and mammalian hosts. Adipose tissue has been implicated as a reservoir of infection for viruses including HIV and mouse adenovirus type 1, bacterial pathogens, including *Mycobacterium tuberculosis*, which resides inside adipocytes of fat tissue and parasites such as *Trypanosoma cruzi*. Furthermore dendritic cells, which are pivotal in initiating immune responses, exist in adipose tissue which they use as an energy source. Whilst we detected a fluorescent signal associated with adipose tissue in all cases (and this was specific to mCherry and not general fluorescence), we were only able to isolate predator once from adipose tissue. This could reflect that standard isolation process of predator may be insufficient for adipose tissue or that the predator may not rely on prey-dependent growth. However it cannot be ruled out that some of the detected signal was due to accumulation of the mCherry protein after lysing of the predator in serum. Therefore, further work is required to optimise isolation of viable predator and identify within which specific cell type the predator resides, potentially using qPCR as in other reported studies.

Plague presents as two distinct phases of disease: an extended “pre-inflammatory” phase during which bacterial replication occurs in the absence of discernible disease symptoms or inflammatory responses; and a subsequent “pro-inflammatory” phase characterized by the onset of symptoms, dramatic increases in cytokines, neutrophils, and inflammatory lung pathology. Maintenance of the extended pre-inflammatory state, despite inflammasome activation, allows for unimpeded bacterial replication. In our studies, the presence of *B. bacteriovorus* HD100 alone did not have a deleterious effect in either mouse strain, which supports the finding that dosing i.n. or i.v. with BALOs resulted in a modest but short-lived inflammatory response in mice with no impact on survival. Similarly, human phagocytic cells produced lower pro-inflammatory cytokine levels when infected with HD100.
**Bdellovibrio** versus two members of the *Enterobacteriaceae*\(^\text{29}\). *B. bacteriovorus* HD100 provided significant protection from *Y. pestis* in SKH-1 mice. It is not possible to define the mechanism by which *B. bacteriovorus* HD100 was protective, for example if it involves active predation, triggering the host to respond to the infection

---

**Figure 2.** mCherry signal can be detected *in vivo* over 96 h after a single dose of *B. bacteriovorus* HD100:mCherry. Total body fluorescence (570/620 nm) of mice (groups of 3) dosed via the i.v., i.p., i.n., or s.c. routes with either a single dose of HD100:mCherry or PBS imaged daily for up to 5 days, except for s.c. groups which were not imaged until Day 3 due to technical issues. Data presented as fold change in mCherry signal in HD100:mCherry dosed mice compared to the signal in PBS-dosed mice on the dorsal side (black bars) and the ventral side (grey bars). Included for reference is a representative mouse from PBS- or HD100:mCherry-dosed groups imaged on the final day (all final day images are included in Supplementary Fig. S1).
or by blocking entry into phagocytic cells. The preliminary data suggests that there may be a strain specific effect as similar protection was not seen in Balb/c mice (Fig. 7). Whilst the Balb/c mouse is well characterised, less is known about SKH-1 mice. The SKH-1 mouse, being hairless, was originally used for dermatologic and wound

Figure 3. SKH-1 mice dosed with *B. bacteriovorus* HD100:mCherry had a strong signal associated with the inguinal adipose tissue. Top - representative picture of a mouse dosed with HD100:mCherry or PBS showing signal located with inguinal adipose tissue. Bottom - levels of mCherry signal detected in adipose tissue of mice dose with HD100:mCherry via four different routes. Data presented as fold change in mCherry signal in adipose tissue isolated from HD100:mCherry-dosed mice compared to the signal in control adipose tissue isolated from PBS-dosed mice.

Figure 4. Predator isolated from fat from a mouse dosed with *B. bacteriovorus* HD100:mCherry (left) was enumerated by plaque assay and imaged using the IVIS. As a comparison, adipose tissue from mice dosed with PBS (right) was also processed and imaged.
Figure 5. *B. bacteriovorus* HD100:mCherry protects SKH-1 mice from a lethal challenge of *Y. pestis*. (a) Survival curves of mice infected with *Y. pestis* CO92 pGEN-luxCDABE and treated with PBS (black lines) or HD100:mCherry (grey lines). Significance was evaluated using a log-rank test. (b) Bio-luminescence data from mice upon culling which were untreated, survivors or non-survivors. The grey dotted line is the level of background signal. The images are from a representative mouse from the PBS-treated (top) or HD100:mCherry-treated (bottom) groups from Experiment 1. *** = p < 0.001, **** = p < 0.0001, based on a two tailed, un-paired t-test.

Figure 6. No significant difference between host responses in mice infected with a lethal dose of *Y. pestis* CO92 pGEN-luxCDABE in the presence or absence of *B. bacteriovorus* HD100:mCherry. Level of induction of cytokines/chemokines in SKH-1 mice infected with *Y. pestis* in the presence (grey bars) or absence (white bars) of *B. bacteriovorus* HD100, compared to the levels found in uninfected mice dosed with PBS, expressed as fold change (log2).
healing research (reviewed by31). The strain is immunocompetent, outbred, unpigmented and genetically uncharacterised. The immunobiology of various hairless strains has been evaluated32 and although some differences are reported with responses in fully furred mouse strains, these mice can reject skin allografts and form antibodies normally. In addition, humoral and cellular immunity of the SKH1 mouse line determined that blood counts, immunoglobulin levels, and CD4+ and CD8+ T cells were comparable between SKH1 and the C57BL/6 strain33. Well-established paradigm states simplistically that C57BL/6 mice show Th1 biased immune responses, while Balb/c mice have more balanced responses, with a tendency towards Th2. This is reflected in differences in the ability to generate protective responses upon immunisation and subsequent challenge for some pathogens eg Francisella tularensis34, or in differences between inbred mouse strains in the level of resistance to eg Pseudomonas aeruginosa infection 35. Both C57BL/6 and Balb/c mice are susceptible to Y. pestis, whereas Mus spretus SEG mice can resist Y. pestis and develop an immune response characterized by a strong recruitment of M1 macrophages36. This resistance correlated with stronger bactericidal activity with higher nitric oxide production, a more pro-inflammatory polarized cytokine response, and a higher resistance to Y. pestis-induced apoptosis36. In addition, other studies have shown that the dampening of the immune response in Y. pestis infected mice with corticosteroids improves bacterial clearance, immunopathology and survival in mice receiving antibody therapy37. In our studies, analysis of the host response to a single dose of B. bacteriovorus HD100 in Y. pestis-infected mice showed that there was a differential host response, with three pro-inflammatory cytokines being higher in SKH-1 mice than Balb/c mice. Therefore given the role that the immune response can have to the outcome of plague, the increase in pro-inflammatory cytokines suggest that SKH-1 were able to control Y. pestis proliferation in vivo by ablation of the pre-inflammatory stage of plague. Alternatively, SKH-1 mice were able to control the harmful inflammatory response of late infection whilst allowing predation to work synergistically with the immune system to remove the pathogen. Further work is required to delineate the relative contribution of predation or immune response to outcome.

Figure 7. B. bacteriovorus HD100:mCherry is protective in SKH-1 mice but not in Balb/c mice. (a) Survival curves of SKH-1 (left) or Balb/c (right) mice infected with Y. pestis CO92 pGEN-luxCDABE and treated with PBS (black lines) or HD100:mCherry (grey lines). (b) Levels of induction of cytokines/chemokines of Y. pestis infected Balb/c and SKH-1 mice treated with HD100. Data is displayed as fold change (log2) compared to baseline levels (uninfected mice dosed with PBS) for HD100:mCherry-treated Balb/c mice (white bars) and HD100:mCherry-treated SKH-1 mice (grey bars). * = p < 0.05, **** = p < 0.0001, based on a two-way ANOVA with Sidak’s correction for multiple comparisons.
The finding that *B. bacteriovorus* HD100 protected SKH−1 mice from lethal challenge with *Y. pestis* expands the potential opportunities for predatory bacteria to be used therapeutically. This is consistent with a recent observation that repeated dosing with *Bdellovibrio* reduced colonisation of the lung in pneumonic plague, although impact on survival was not reported40. In this study, the therapy was delivered pre-exposure and then given once a day. Further studies are needed to determine the effect of post-exposure therapy, as well as if more than one daily dose could be given. However, Balb/c mice data suggests that the effects of predatory bacteria in vivo may be complex and need to be elucidated if predatory bacteria are to be used as a therapeutic. Similarly the interaction between the predatory bacteria and the host immune system, and how this affects disease progression, needs to be elucidated to determine the relative contribution of predation vs immune response to protection. Therefore whilst this is the first report of protection against systemic challenge in a mammalian model, further work is needed to evaluate the utility of predatory bacteria as a therapeutic.

**Methods**

**Buffers and media.** Ca/HEPES buffer: 5.49 g/l HEPES free acid, 0.284 g/l calcium chloride dehydrate, pH 7.6. YPSC overlay agar: 0.25 g/l magnesium sulphate, 0.5 g/l sodium acetate, 1 g/l Bacto peptone, 1 g/l yeast extract, 6 g/l agar, pH 7.6; adjust to 0.25 g/l anhydrous calcium chloride after autoclaving. YPSC ‘hard’ agar: same as overlay agar except 10 g/l agar added.

**Growth and preparation of predatory *B. bacteriovorus* HD100.** *B. bacteriovorus* HD100:mCherry, a strain which a mCherry fluorescence protein tag on the Bd0064 protein, was grown as previously described39,40. Briefly, *B. bacteriovorus* stocks were prepared by culture on stationary phase *E. coli* S17−1 prey suspended in Ca/HEPES buffer (5.49 g/l HEPES free acid, 0.284 g/l calcium chloride dehydrate, pH 7.6). *E. coli* cells were grown for 16 h in L broth at 37 °C. To grow predator, a ratio of 3:1 prey: predator was used and cultures incubated at 28 °C for 24 h at 180 rpm. After two 24 h cultures, the resultant lysate was used to set up cultures for the experiments. For assays, cultures ranging from 10−100–250 ml were set up and incubated for 40 h. To purify and concentrate predator, the lysate was passed through a 0.45 µm filter and pelleted and washed twice with PBS by centrifugation. After the final wash, the cells were re-suspended in a sterile PBS at a 100x concentrated stock. Predator input was subsequently enumerated by serial dilution and enumeration of plaques in YPSC overlay agar (containing *E. coli* S17−1) which was on top of YPSC hard agar as previously described40. For heat-killed predator, prepared predator was incubated at 105 °C for 10 mins, followed by cooling and enumerated to confirm that no viable predator could be detected.

**Intracellular persistence of *B. bacteriovorus* HD100 in murine macrophages.** The J774.1 murine macrophage cell line was seeded in wells of a 24-well plate at 3 × 10⁵ cells/well in DMEM supplemented with 10% foetal calf serum (FCS) and 2 mM glutamine. Cells were incubated overnight, and in the morning the media was removed and cells washed with PBS. Predator was added in L-15 media supplemented with 2% FCS and the cells/predator incubated for 2.5 h in a 37 °C, non-CO₂ incubator. After this incubation time, gentamicin was added to the cells at 50 µg/ml gentamicin (final concentration) and the cells incubated for a further 0.5 h. The input was removed and fresh media containing gentamicin. At set times, the cell medium was removed, cells washed twice with PBS and then the cells lysed by addition of dH₂O. Viable predator was then enumerated by overlay assays. Prior to infection and at each sampling time, monolayers were visually examined. For ImageStream analysis, rather than cells being lysed by addition of dH₂O, cells were scraped into PBS, stained with 40 nM Lysotracker Deep-Red and Hoescht 33342 dye and run on the ImageStream X. Over 7,000 events were collected and analysed using the following strategy: identification of single cells, identification of these with mCherry signal and then within this subset, the level of co-localisation of the masks set for the mCherry signal and the Deep-Red signal. Across all three experiments, the average number of cells collected was 7521 cells, and of these, 92% of the cells within this subset, the level of co-localisation of the masks set for the mCherry signal and the Deep-Red signal.

**Growth and preparation of *Y. pestis*.** *Y. pestis* CO92 pGEN-luxCDABE22 was grown for ~16 h in BAB broth supplemented with 50 µg/ml ampicillin at 28 °C, 180 rpm in a shaking incubator until OD₅₉₀ was 0.6 (an OD which is approximately 1 × 10⁸ cfu/ml). The culture was then diluted to the appropriate concentration in PBS and used for the challenge. The challenge dose was subsequently enumerated after challenge by determining viable colonies on BAB plates (supplemented with haemin and 50 µg/ml ampicillin) and incubated at 28 °C for 3–4 days. For enumeration of *Y. pestis* from mice, organs were removed, homogenised in PBS through a cell sieve and plated onto BAB agar containing 50 µg/ml ampicillin.

**Animal studies.** All procedures involving animals were conducted in strict accordance with the Animals (Scientific Procedures) Act 1986 under project licence 30-3166. This project licence was approved following an ethical review by Dstl’s Animal Welfare and Ethical Review Body. Female Balb/c mice, and male or female immune-competent but hairless SKH-1 mice (both supplied by Charles River Laboratories) aged 6–8 weeks old, were used in these studies. On arrival, mice were randomly assigned to groups (group size defined in figure legends) and allowed to acclimatise to biosafety level 3 isolator conditions for a minimum of 5 days. Prior to challenge, mice were given approximately 1 × 10⁶ pfu of mcherry expressing *Bdellovibrio* in a total volume of 50 µl by the i.p. route. Mice were subsequently challenged approximately 2 h later with ~1000 pfu of *Y. pestis* CO92 pGEN-luxCDABE given in a volume of 100 µl by the s.c. route on the dorsal side. Mice were administered a single dose (50 µl i.p.) of the freshly-prepared predator daily, until the end of the studies. Control mice were treated identically but given PBS instead of predator. For imaging studies, mice were anaesthetised using
ketamine-metomidine (0.78 mg Ketaset, Fort Dodge Animal Health Ltd, Southampton, and 0.015 mg Domitor, Elanco, Basingstoke, given in a total volume of 200 µl i.p.) and once unconscious, imaged using an IVIS Spectrum (Caliper, Perkin Elmer, USA) and images captured and analysed using the Living Image (ver. 4.5) software to detect bioluminescence or fluorescence signal, using the built-in auto-exposure function of the software. To reduce background fluorescence mice were fed an alfalfa-free diet (AIN93M, LabDiet) from 7 days before the start of the studies. After imaging, mice were recovered using Atipamezole (Antisedan, Janssen Animal Health, High Wycombe, 0.05 mg in 133 µl i.p.) for imaging on consecutive days. Whilst under anaesthetic mice were kept in a warming box and closely observed until fully recovered. Mice were weighed daily and checked at least twice daily for clinical signs of disease. Upon reaching predetermined humane end points mice were culled by cervical dislocation.

**Cytokine assay.** Blood samples were obtained from anaesthetised mice (groups of 3 mice) via cardiac puncture. The blood was incubated at room temperature to allow the blood to clot and the samples centrifuged at 11,000 rpm for 15 minutes. The serum was removed and stored in −80 °C and assayed at a later date using Bio-Rad Luminex 23-plex, group 1 pro-inflammatory cytokine assay kit. Briefly, samples were thawed, processed according to manufacturer's instructions (using neat serum) and analysed on a Bio-Rad Plex 200 system.

**Statistics.** Survival curves were compared using the log-rank test on Graphpad v6. Stratified log-rank tests were performed on SPSS. The luciferase data for adipose tissue was analysed using a two tailed, un-paired t-test of the log transformed data (t = 9.261 df = 7). Cytokine log2 data was analysed by a two-way ANOVA with Sidak's correction for multiple comparisons on Graphpad v6 (df = 92). All error bars shown are standard error of the mean.

**Data Availability**

All relevant data are within the paper or the Supplementary Fig. online.

**References**

1. Cox, J. A. G. & Worthington, T. The 'Antibiotic Apocalypse' - Scaremongering or Scientific Reporting? Trends in microbiology 25, 167–169. https://doi.org/10.1016/j.tim.2016.01.016 (2017).
2. Sockett, R. E. & Lambert, C. Bdellovibrio as therapeutic agents: a predatory renaissance? Nature reviews. Microbiology 2, 669–675. https://doi.org/10.1038/nrmicro959 (2004).
3. Dashiff, A., Junka, R. A., Libera, M. & Kadouri, D. E. Predation of human pathogens by the predatory bacteria *Micavibrio aeruginosavorus* and *Bdellovibrio bacteriovorus*. Journal of applied microbiology 110, 431–444. https://doi.org/10.1111/j.1365-2672.2010.04990.x (2011).
4. Kadouri, D. E., Shanks, K. & Døi, R. M. Y. Prey predatory bacteria: a potential ally against multidrug-resistant Gram-negative pathogens. Plos one 8, e63397. https://doi.org/10.1371/journal.pone.0063397 (2013).
5. Kuenen, J. G. & Rittenberg, S. C. Incorporation of long-chain fatty acids of the substrate organism by *Bdellovibrio bacteriovorus* during intraperiplasmic growth. Journal of bacteriology 121, 1145–1157 (1975).
6. Nelson, D. R. & Rittenberg, S. C. Incorporation of substrate cell lipid A components into the lipopolysaccharide of intraperiplasmically grown *Bdellovibrio bacteriovorus*. Journal of bacteriology 147, 860–868 (1981).
7. Rosson, R. A. & Rittenberg, S. C. Regulated breakdown of *Escherichia coli* deoxyribonucleic acid during intraperiplasmic growth of *Bdellovibrio bacteriovorus* 109J. Journal of bacteriology 140, 620–633 (1979).
8. Talley, B. G., McDade, R. L. Jr. & Diedrich, D. L. Verification of the protein in the outer membrane of *Bdellovibrio bacteriovorus* as the OmpF protein of its *Escherichia coli* prey. Journal of bacteriology 169, 694–698 (1987).
9. Thomashow, M. F. & Rittenberg, S. C. Intraperiplasmic growth of *Bdellovibrio bacteriovorus* 109J; solubilization of *Escherichia coli* peptidoglycan. Journal of bacteriology 135, 998–1007 (1978).
10. Schwudke, D. et al. The obligate predatory *Bdellovibrio bacteriovorus* possesses a neutral lipid A containing alpha-D-Mannoses that replace phosphate residues: similarities and differences between the lipid A and the lipopolysaccharides of the wild type strain B. *bacteriovorus* HD100 and its host-independent derivative Hf100. The journal of biological chemistry 278, 27502–27512, https://doi.org/10.1074/jbc.M303012200 (2003).
11. Atterbury, R. J. et al. Effects of orally administered *Bdellovibrio bacteriovorus* on the well-being and *Salmonella* colonization of young chicks. Applied and environmental microbiology 77, 5794–5803. https://doi.org/10.1128/aem.00426-11 (2011).
12. Shatzkes, K. et al. Examining the safety of respiratory and intravenous inoculation of *Bdellovibrio bacteriovorus* and *Micavibrio aeruginosavorus* in a mouse model. Scientific reports 5, 12899. https://doi.org/10.1038/srep12899 (2015).
13. Shatzkes, K. et al. Examining the efficacy of intravenous administration of predatory bacteria in rats. Scientific reports 7, 1864. https://doi.org/10.1038/s41598-017-02041-3 (2017).
14. Willis, A. R. et al. Injections of Predatory Bacteria Work Alongside Host Immune Cells to Treat Shigella Infection in Zebrafish Larvae. Current biology: CB 26, 3343–3351. https://doi.org/10.1016/j.cub.2016.09.067 (2016).
15. Shatzkes, K. et al. Predatory Bacteria Attenuate *Klebsiella pneumoniae* Burden in Rat Lungs. mBio 7, https://doi.org/10.1128/ mBio.01847-16 (2016).
16. Boileau, M. J. et al. Efficacy of *Bdellovibrio bacteriovorus* 109J for the treatment of dairy calves with experimentally induced infectious bovine keratoconjunctivitis. American journal of veterinary research 77, 1017–1028, https://doi.org/10.2460/ajvr.77.9.1017 (2016).
17. Russo, R. et al. Susceptibility of Select Agents to Predation by Predatory Bacteria. Microorganisms 3, 903–912. https://doi.org/10.3390/microorganisms3030903 (2015).
18. Prentice, M. R. & Rahalison, L. Plague. Lancet (London, England) 369, 1196–1207, https://doi.org/10.1016/S0140-6736(07)60566-2 (2007).
19. Guiyoule, A. et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of *Yersinia pestis*. Emerging infectious diseases 7, 43–48. https://doi.org/10.3201/eid0701.00043 (2001).
20. Silva, M. T. & Pestana, N. T. The in vivo extracellular life of facultative intracellular bacterial parasites: role in pathogenesis. *Immunobiology* 218, 325–337, https://doi.org/10.1007/s00785-012-0511-3 (2013).
21. Williamson, E. D. et al. Immunogenicity of the R1+ R+ vaccine for plague with identification of potential immune correlates. *Microbial pathogenesis* 42, 11–21. https://doi.org/10.1016/j.micpath.2006.09.003 (2007).
22. Flick-Smith, H. C. et al. Establishing an In Vivo Imaging Capability in High-Containment. *Applied Biosafety* 21, 5–11. https://doi.org/10.1177/1535676016631878 (2016).
23. Couturier, J. & Lewis, D. E. HIV Persistence in Adipose Tissue Reservoirs. *Current HIV/AIDS reports* 15, 60–71, https://doi.org/10.1007/s11904-018-0378-z (2018).
24. Molloy, C. T., Adkins, L. J., Griffin, C., Singer, K. & Weinberg, J. B. Mouse adenovirus type 1 infection of adipose tissue. *Virus research* **244**, 90–98, https://doi.org/10.1016/j.virusres.2017.11.014 (2018).
25. Beigier-Bompadre, M. et al. *Mycobacterium tuberculosis* infection modulates adipose tissue biology. *PLoS pathogens* **13**, e1006676, https://doi.org/10.1371/journal.ppat.1006676 (2017).
26. Ferreira, A. V. et al. Evidence for Trypanosoma cruzi in adipose tissue in human chronic Chagas disease. *Microbes and infection* **13**, 1002–1005, https://doi.org/10.1016/j.micinf.2011.06.002 (2011).
27. Knight, S. C. Specialized perinodal fat fuels and fashions immunity. *Immunity* **28**, 135–138, https://doi.org/10.1016/j.immuni.2008.01.003 (2008).
28. Lebba, V. et al. Higher prevalence and abundance of *Bdellovibrio bacteriovorus* in the human gut of healthy subjects. *PLoS one* **8**, e61608, https://doi.org/10.1371/journal.pone.0061608 (2013).
29. Sivaraman, V. et al. *Yersinia pestis* activates both IL-1beta and IL-1 receptor antagonist to modulate lung inflammation during pneumonic plague. *PLoS pathogens* **11**, e1004688, https://doi.org/10.1371/journal.ppat.1004688 (2015).
30. Raghunathan, D. et al. Engagement, persistence and fate of *Bdellovibrio bacteriovorus* predators inside human phagocytic cells informs their future therapeutic potential. *Scientific reports* **9**, 4293, https://doi.org/10.1038/s41598-019-40223-3 (2019).
31. Benavides, F., Oberson, B., VanBuskirk, A. M., Reeve, V. E. & Kusewitt, D. F. The hairless mouse in skin research. *Journal of dermatological science* **53**, 10–18, https://doi.org/10.1016/j.jdermsci.2008.08.012 (2009).
32. Hemmings, R. M., Forbes, P. D. & Linna, T. J. Immune responses in non-hair mice. *International archives of allergy and applied immunology* **67**, 254–261 (1982).
33. Schaffer, B. S. et al. Immune competency of a hairless mouse strain for improved preclinical studies in genetically engineered mice. *Molecular cancer therapeutics* **9**, 2354–2364, https://doi.org/10.1158/1535-7186.mct-10-0207 (2010).
34. Chen, W., Shen, H., Webb, A., Kuo, Lee, R. & Conlan, J. W. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. *Vaccine* **21**, 3690–3700 (2003).
35. Kondratieva, T. K. et al. Characterization of T cell clones derived from lymph nodes and lungs of *Pseudomonas aeruginosa*-susceptible and resistant mice following immunization with heat-killed bacteria. *Clinical and experimental immunology* **121**, 275–282 (2000).
36. Pachulec, E. et al. Enhanced Macrophage M1 Polarization and Resistance to Apoptosis Enable Resistance to Plague. *The Journal of infectious diseases* **216**, 761–770, https://doi.org/10.1093/infdis/jix348 (2017).
37. Levy, Y. et al. Adjunctive Corticosteroid Treatment Against *Yersinia pestis* Improves Bacterial Clearance, Immunopathology, and Survival in the Mouse Model of Bubonic Plague. *The Journal of infectious diseases* **214**, 970–977, https://doi.org/10.1093/jid/ jiw290 (2016).
38. Russo, R. et al. Susceptibility of Virulent *Yersinia pestis* Bacteria to Predator Bacteria in the Lungs of Mice. *Microorganisms* **7**, https://doi.org/10.3390/microorganisms7010002 (2018).
39. Carey, L. & Elizabeth, S. R. Laboratory Maintenance of *Bdellovibrio*. *Current Protocols in Microbiology* **9**, 7B.2.1–7B.2.13, https://doi.org/10.1002/9780470172925.sacb7b02x9 (2008).

**Acknowledgements**

This work was performed by Dstl as a subcontractor to the University of Nottingham under Cooperative Agreement Number W911NF-15-2-0028, funded by the U.S. Army Research Office and the Defense Advanced Research Projects Agency (DARPA). *Bdellovibrio* strains and advice on their culture was provided by Prof RE Sockett and Dr J Tyson. The views and conclusions contained in this document are those of Dstl and should not be interpreted as representing the official policies, either expressed or implied, of the U.S. Army Research Office, DARPA, or the U.S. Government. The U.S. Government is authorized to reproduce and distribute reprints for Government purposes notwithstanding any copyright notation hereon.

**Author Contributions**

Experiments were designed by J.S.F., H.E.S., I.A.C., P.C.F.O. and E.D.W. Experiments were performed by J.S.F., E.K. and H.E.S. The paper was written by J.S.F., P.C.F.O. and E.D.W.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-019-43467-1.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019